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Diabetes mellitus is a metabolic disease caused by both
genetic and environmental factors. The pathogenic mech-
anism(s) of diabetes are complex, and the complicated
networks related to this disease involve distinct signaling
pathways. Evidence has recently been provided that ER stress
might be involved in the pathogenesis of diabetes and its
complications. Early steps in the maturation of secretory
proteins take place in the ER, for example, the folding
of the nascent polypeptide chains and posttranslational
modiﬁcations important for proper folding and function
of the protein. At a stage (due to several metabolic dis-
turbances), when unfolded polypeptide exceeds the folding
and/or processing capacity of the ER, cells are susceptible
to a phenomenon referred to as “ER stress.” Under these
conditions, speciﬁc signaling pathways, termed the unfolded
protein response (UPR), are activated to return the ER
to its normal physiological state. Prolonged activation of
the ER stress and the UPR can lead to cell pathology and
subsequent tissue dysfunction. There is now ample evidence
that the UPR is chronically activated in many disease states
including diabetes and its complications. Therefore, a better
understanding of the pathways regulating ER stress and UPR
is warranted in order to be instrumental for the design of
novel therapies for diabetes and its complications.
In this focused issue of the journal, we have assembled
several invited reviews, from well-recognized experts in their
ﬁelds, as well as original research articles. These reviews
provide state-of-the-art knowledge dealing with several
mechanisms not only related to the genesis of diabetes
but also to its progression to diabetic complications, all of
which potentially originate or converge from chronic ER
stress. In addition, several excellent original research articles
demonstrate novel pathophysiologic aspects of diabetes with
mechanistic studies central to ER stress and give hope
and directionality for identifying new drug targets and
developing newer therapeutic measures.
Of all the professional secretory cells we possess, β-cells
are the most sensitive to ER stress because of the large
ﬂuctuations in protein synthesis (including insulin) they face
daily. M.-K. Kim et al. have reviewed how this “protein
quality-control machinery” of the cell is responsible for
appropriate insulin biosynthesis and how ER stress plays an
important role in the impairment of insulin biosynthesis.
J. Zhong et al. have summarized the status on how ER
stress plays an essential role in autoimmune-mediated β-cell
destruction and also pointed out how ER stress regulates
the functionality of immune cells relevant to autoimmune
progression during Type 1 diabetes development. In an
attempt to improve islet transplantation in humans, the
molecular mechanism of apoptosis in β cells of islets in the
transplantation setting needs to be clearly understood. In
this context, M. Wang et al. have discussed their original
researchworkonhumanisletssubjectedtomultiplestressors
and delineated several apoptotic pathways originating from
oxidative stress, autophagy, and ER stress.
While ER stress is emerging as a unifying paradigm
in diabetes and its complications, several recent studies,
emphasized a deﬁnite role of ER stress in retinal, podocyte,
and neuronal cell apoptosis. G. Jing et al. have summarized
the recent progress on ER stress and apoptosis in retinal
diseases, focusing on various proapoptotic and antiapoptotic
pathways that are activated by the UPR and discussed how2 Experimental Diabetes Research
these pathways contribute to ER stress-induced apoptosis in
retinal cells. Considering the fact that ER stress is initially
an adaptive response, studying ER stress-related factors
appear to unravel novel drug targets to prevent and treat
diabetic retinopathy. In this connection, W. -K. Hu et
al. have explained the role of P58IPK and ER-associated
degradation (ERAD) of unfolded protein which prevents
ER stress and reduce retinal vascular leakage under high-
glucose conditions. While thioredoxin interacting protein
(TXNIP) has been recently identiﬁed as an early response
gene highly induced by diabetes and hyperglycemia, its role
in the pathogenesis of diabetic retinopathy is not clearly
understood. Using appropriate animal model and retinal
Muller cell line and several molecular biology techniques,
T. S. Devi et al. have described how upregulation of
TXNIP evokes a program of cellular defense and survival
mechanism(s) that ultimately lead to oxidative stress, ER-
stress, inﬂammation, and apoptosis.
Despite a great deal of research, the mechanisms that
may link high-glucose concentrations to the molecular
and cellular pathways of diabetic atherogenesis are not
fully understood. D. R. Beriault and G. H. Werstuck have
summarized the current state of our knowledge of pathways
and mechanisms that may link diabetes and hyperglycemia
to atherogenesis highlighting the recent work from their
lab (and others) that supports a role for ER stress in these
processes. Although recent studies have shown that pertur-
bations in lipid metabolism cause an ER stress response, very
little is known about the mechanism of UPR activation by
perturbations in glucose and lipid metabolism. Moreover,
it has been demonstrated that 4-phenylbutyrate (4-PBA)
and tauroursodeoxycholic acid (TUDCA), which are two
diﬀerent chemical structures having chemical chaperone
activity in common, relieve ER stress. Using THP-1 human
monocytes as a surrogate cell model and utilizing several
molecular biology techniques, R. Lenin et al. have demon-
strated that monocytes subjected to glucolipotoxicity exhib-
ited increased UPR responses (as evidenced by increased
mRNA expression of several ER stress markers) along with
increased oxidative stress and apoptosis. Interestingly, ER
stress inducted by glucolipotoxicity was shown resisted by
PBA. These observations constitute an important proof of
principle that manipulation of the ER system to decrease ER
stress by chemical agents may have therapeutic implications
for diabetes and its complications.
Lastly, the prevalence of nonalcoholic fatty liver disease
(NAFLD) has increased in parallel with the epidemics of
obesity and type 2 diabetes, which are risk factors for
NAFLD. Whereas the association of type 2 diabetes with
microvascular complications and macrovascular disease is
well established, the association of type 2 diabetes with
NAFLD is only recently recognized and so are the inter-
relatedpathogenicmechanisms.Usingsteatohepatitisanimal
model and HepB3 cells, M. K. Chae et al. have demonstrated
that Pentoxifylline (a known anti-inﬂammatory agent)
attenuates methionine and choline-1-deﬁcient diet-induced
steatohepatitis by suppressing ER stress.
These papers, hopefully, will provide better understand-
ing of ER stress and UPR pathway involvement in the
pathogenesis of diabetes and its complications and bring
forward new and innovative ideas with respect to the
development of eﬃcient and adjuvant treatment modalities.
Considering the involvement of ER stress in multiple tissues
and their convergence in multiple pathogenic pathways
(oxidative stress, inﬂammation, apoptosis, autophagy, and
proteasomal degradation), targeting the ER stress pathway
appears as a promising therapeutic strategy. The signiﬁcant
side eﬀects with existing drugs and the demand for newer
molecules with improved safety and a diﬀerent mode
of action justiﬁes this directionality. In fact, it has been
reported that chemical ER chaperones can reduce ER stress,
suggesting that small molecules can aﬀect ER stress signaling
in disease states. There is also much hope in investigating
the traditional plant principles of medicinal claims to see
whether they act as beneﬁcial ER stress modulators. Given
the possible development of novel UPR-targeted therapies
for diabetes and its complications, it is essential to know
which components of the ER stress response to target and
which particular disease stage will be most amenable to
therapy.
Although there is an enormous progress in studying the
ER stress aspects, the list of unresolved queries in the stress
mediated pathway of ER dysfunction in diabetes and its
complications warrant continued research eﬀorts. Obviously
not all aspects of this exciting ER stress ﬁeld could be
addressed in one issue and we extend our apologies to many
contributors of this ﬁeld whose work has not been covered.
Wethankalltheauthorswhocontributedtothisspecialissue
of EDR and the reviewers for the highly constructive and
helpful comments.
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